China's share of drug candidates entering clinical trials rises 2.7-fold in a decade
Biotech industry: "Excessive regulation weakens competitiveness"
Concerns over reduced opportunities for drug development and patient treatment

As the United States moves to expand investment restrictions on China’s biotechnology industry, concerns are mounting in the U.S. pharmaceutical and biotech sectors about the unintended consequences of regulation. With China emerging as a major partner for global pharmaceutical companies in developing new drugs, critics say broad investment restrictions could hamper U.S. companies’ drug development efforts and limit patients’ access to treatment.


According to the biotech industry on October 27, the U.S. government announced a proposed rule on October 22 local time to add biotechnology to the scope of the Outbound Investment Security Program (OISP). The proposal would restrict certain equity investments and joint ventures involving Chinese companies developing antibody drugs and cell and gene therapies, following similar restrictions on semiconductors, artificial intelligence (AI) and quantum technologies. The aim is to prevent U.S. capital from being used to develop technologies for China’s military or surveillance purposes; it would not ban the licensing of new drug technologies or the sale of pharmaceuticals themselves.


U.S. Clamps Down on China Biotech Investment... Dilemma Over New Drug Collaboration View original image

The U.S. biotech industry is wary that the scope of the regulations could become excessively broad. Shortly after the proposed rule was announced, the Biotechnology Innovation Organization (BIO) said, “Regulation alone cannot ensure success,” adding that “broad regulations could increase uncertainty for innovative companies and investors and weaken the competitiveness of the U.S. biotech industry.” The Massachusetts Biotechnology Council also stressed the importance of international collaboration to bring promising drugs developed overseas into U.S. development pipelines, saying that patients’ access to innovative treatments should not be delayed.


These concerns stem from the growing prominence of new drugs developed in China. According to Goldman Sachs, Chinese companies developed 46% of the drug candidates that entered human clinical trials for the first time worldwide in the first half of 2025, up 2.7-fold from about 17% a decade earlier. In the first half of 2026, China recorded 81 technology-export deals for innovative drugs, with potential contract values totaling about $110 billion. China has grown beyond a manufacturing base for generic drugs and active pharmaceutical ingredients to become a major market where global pharmaceutical companies source drug candidates.


As China’s drug development capabilities have grown, U.S. pharmaceutical companies have diversified their approaches to collaboration. Last year, Pfizer paid $1.25 billion upfront to license the development and commercialization rights to a bispecific antibody cancer drug from China’s 3SBio and also made an equity investment worth $100 million. If the proposed rule is finalized, equity investments in similar deals could be restricted even if technology licensing remains permitted. This has raised concerns that investment and business partnerships to secure new drugs from China could face constraints.


China, too, is tightening controls on key biotechnology. On October 16, China’s Ministry of Commerce and Ministry of Science and Technology announced a proposal to add five types of biopharmaceutical technologies, including cell and gene therapies and small interfering RNA (siRNA), to its list of technologies subject to export bans or restrictions. However, the proposal would provide exceptions or streamlined procedures for certain overseas technology-use agreements and contract research and manufacturing. The aim is to control the transfer of key technologies overseas while maintaining the international collaboration needed to develop new drugs.



As China has grown into a major source of innovative drugs, the United States faces an increasingly difficult balancing act. It needs to counter China’s efforts to develop advanced biotechnology, but must also avoid stifling the collaboration U.S. pharmaceutical companies need to develop new drugs. The U.S. patient advocacy group Patients Rising urged regulators to narrow the scope of the restrictions, saying they should distinguish between technologies that threaten national security and treatments that patients are waiting for. The U.S. Treasury Department will solicit comments through December 7 before issuing a final rule.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing